Tack, Lloyd J. W. Craen, Margarita Dhondt, Karlien Vanden Bossche, Heidi Laridaen, Jolien Cools, Martine
Published in
Biology of Sex Differences
BackgroundPrior to the start of cross-sex hormone therapy (CSH), androgenic progestins are often used to induce amenorrhea in female to male (FtM) pubertal adolescents with gender dysphoria (GD). The aim of this single-center study is to report changes in anthropometry, side effects, safety parameters, and hormone levels in a relatively large cohor...
Tasci, Yasemin Polat, Oznur Gokcag Ozdogan, Serdinc Karcaaltincaba, Deniz Seckin, Levent Erkaya, Salim
Published in
Archives of Gynecology and Obstetrics
PurposeTo evaluate the treatment of simple endometrial hyperplasia without atypia with different gestagens.MethodsSixty premenopausal women with histologically documented endometrial hyperplasia without atypia were included in this prospective controlled study. Patients were randomized into two groups: Group I included 30 patients who received lyne...
Lauritzen, C
Published in
Maturitas
The clinical use of estrogens and progestogens for menopausal women is reviewed, discussing the indications, results of studies on effectiveness of various agents o each target organ, contraindications, risk-benefit ratio, and types of drug preparations available and used in European countries. The indications for menopausal hormone replacement are...
Frohlich, E P
Published in
Obstetrical & gynecological survey
5 cases of vascular complications--hemorrhagic stroke, myocardial infarction, retinal vein thrombosis, thrombotic stroke and deep vein thrombosis--in young women taking low dose oral contraceptives are described from the Department of Obstetrics and Gynecology, University of the Witwatersrand, Johannesburg, South Africa. The hemorrhagic stroke occu...
L'Hermite, M
Published in
Maturitas
The risks and benefits of specific types of postmenopausal estrogens and progestogens are explored: those affecting serum lipids, clotting elements, hepatic proteins synthesis, blood pressure, glucose tolerance, endometrial, breast and cervical cancer. Ethinyl estradiol taken orally is the only estrogen likely to cause gall bladder disease. It also...
Ruokonen, A Käär, K
Published in
European journal of obstetrics, gynecology, and reproductive biology
The effects of 0.125 mg daily doses of the new progestagen, desogestrel, 0.125 mg of levonorgestrel or 5 mg of lynestrenol on serum sex hormone binding globulin (SHBG), cortisol binding globulin (CBG), ceruloplasmin and HDL-cholesterol were studied in 30 healthy female volunteers to compare the possible androgenic and oestrogenic effects of these c...
Wynn, V
Published in
Contraception, fertilité, sexualité
3 large classes of progestins are used in current combined oral contraceptives (OCs): estranes, gonanes, and pregnanes. Estranes, including norethisterone acetate, lynestrenol, norethynodrel, and ethynodiol diacetate, are all related to the base norethisterone and must be metabolized to norethisterone to be active. The gonanes, principally represen...
Wang, C Q
Published in
Sheng zhi yu bi yun = Reproduction and contraception
A general overview of the chemical structures and development of synthetic estrogens and steroid contraceptives is presented. The first truly successful steroid contraceptive, Enovid, was developed in 1960. There are now some 40 steroid contraceptives marketed around the world. The specific properties of various highly effective, long term antiovul...
Pelissier-langbort, C
Published in
Contraception, fertilité, sexualité
Contraceptive use of normal dosed progestins continues to be useful for many women who cannot use other contraceptive methods, but appropriate use depends on perfect knowledge of their modes of action, advantages, disadvantages, dosages, and duration of action. Each progestin has its own indications, and contraindications, and not all progestins ha...
Dallenbach-Hellweg, G
Published in
Pathology, research and practice
In the last 10 years, 28 adenocarcinomas of the endocervix developing in women up to the age of 50 have been encountered at the author's clinic. Of these women, 23 (82%) had taken oral contraceptives (OCs), in most instances continuously for up to 19 years, and for a median of 10 years. During the same period of time, 12 adenocarcinomas in situ of ...
